Skip to main content

Table 4 Post-hoc analysis on main outcomes

From: Prophylactic metformin after antenatal corticosteroids (PROMAC): a double blind randomized controlled trial

  Metformin n = 52 Placebo n = 51 p value
Primary outcome
First 24 hours n = 47a n = 49a  
Hyperglycemia episodesb
 Non GDM 3.9 ± 1.4 4.0 ± 1.7 0.81
 GDM 3.9 ± 1.5 4.4 ± 1.6 0.40
Secondary outcomes
First 24 hours
 Hypoglycemia episodesc    
 Non GDM 0.1 ± 0.2 0.2 ± 0.5 0.23
 GDM 0 ± 0 0.0 ± 0.0 0.48
Second 24 hours n = 46a n = 40a  
Hyperglycemia episodesb
 Non GDM 1.0 ± 1.3 1.1 ± 1.0 0.83
 GDM 1.5 ± 1.0 1.8 ± 1.2 0.70
Hypoglycemia episodesc
 Non GDM 0.8 ± 0.9 0.6 ± 0.8 0.48
 GDM 0.4 ± 0.9 0.3 ± 0.6 0.27
Third 24 hours n = 37a n = 37a  
Hyperglycemia episodesb
 Non GDM 0.5 ± 1.0 0.6 ± 0.8 0.94
 GDM 0.3 ± 0.7 0.7 ± 1.1 0.61
Hypoglycemia episodesc
 Non GDM 0.7 ± 0.9 0.8 ± 0.8 0.37
vGDM 0.9 ± 0.8 1.1 ± 0.9 0.43
Blood sugar profile points 4–9
 Hyperglycemic episodes 2.7 ± 1.5 3.1 ± 1.4 0.16
  3 [2-4] 3 [2-4] 0.15
  1. Data expressed as mean ± standard deviation and number (%). Analyses by Student t test for comparison of means. P > 0.05 for all analyses
  2. aNumber of monitoring compliant patients included in analysis: compliance defined as at least four of the six pre or 2-hour post meal sugar capillary blood profile points done in the relevant 24-hour block of the 3-day trial period
  3. bHyperglycemia is defined as pre meal blood glucose level of ≥ 5.3 mmol/L and 2 hours post prandial/meal blood glucose of ≥ 6.7 mmol/L
  4. cHypoglycemia is defined as capillary blood glucose level ≤ 3.9 mmol/L
\